Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy

Mariana Chavez-MacGregor MD; Jennifer Litton MD; Huiqin Chen MS; Sharon H. Giordano MD; Clifford A. Hudis MD; Antonio C. Wolff MD; Vicente Valero MD; Gabriel N. Hortobagyi MD; Melissa L. Bondy PhD; Ana Maria Gonzalez-Angulo MD

首页> 外文期刊>Cancer >Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy

【24h】

Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy

机译：接受蒽环类和紫杉类类新辅助化疗的乳腺癌患者的病理完全缓解

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

The current study was conducted to evaluate the influence of race/ethnicity and tumor subtype in pathologic complete response (pCR) following treatment with neoadjuvant chemotherapy.

机译：目前的研究旨在评估种族/种族和肿瘤亚型对新辅助化疗后病理完全缓解（pCR）的影响。

著录项

来源
《Cancer》 |2010年第17期|p.4168-4177|共10页
作者
Mariana Chavez-MacGregor MD; Jennifer Litton MD; Huiqin Chen MS; Sharon H. Giordano MD; Clifford A. Hudis MD; Antonio C. Wolff MD; Vicente Valero MD; Gabriel N. Hortobagyi MD; Melissa L. Bondy PhD; Ana Maria Gonzalez-Angulo MD;
展开▼
作者单位

Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;

Breast Medical Oncology Department, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York;

Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;

Department of Epidemiology, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
neoadjuvant chemotherapy; breast cancer; race; pathologic complete response;

机译：新辅助化疗;乳腺癌;种族;病理完全缓解;

相似文献

外文文献
中文文献
专利

1. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. [J] . Chavez Macgregor M, Litton J, Chen H, Cancer: A Journal of the American Cancer Society . 2010,第17期

机译：接受蒽环类和紫杉类类新辅助化疗的乳腺癌患者的病理完全缓解：评估种族/民族的影响。
2. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. [J] . Frederik Marmé, Wiebke Werft, Anne Walter, Breast cancer research and treatment. . 2012,第3期

机译：CD24 Ala57Val基因多态性预测原发性乳腺癌对顺序以蒽环类和紫杉类类新辅助化疗的病理完全反应。
3. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer [J] . Frederik Marmé, Wiebke Werft, Anne Walter, Breast Cancer Research and Treatment . 2012,第3期

机译：CD24 Ala57Val多态性预测原发性乳腺癌对基于蒽环类和紫杉类类药物的新辅助化疗的病理完全缓解
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy [O] . Meiying Li, Fei Ma, Jiayu Wang, 2018

机译：自噬相关基因5（ATG5）RS473543预测接受蒽环类和/或紫杉烷基辅助化疗的三阴性乳腺癌患者的不同无疾病幸存杂志

Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅